课题基金 / 基金详情

ANTIBODIES TO HUMAN TYPE IV COLLAGENASE & ITS INHIBITOR

ANTIBODIES TO HUMAN TYPE IV COLLAGENASE & ITS INHIBITOR
人 IV 型胶原酶抗体
批准号:
3492886
负责人:
CHI-MING LIANG
金额:
$5.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-09-30 至 1993-03-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The degradation of basement membrane is important for leukocyte migration, tissue remodeling, wound healing, angiogenesis and tumor invasion. Type IV collagen, the major component of basement membrane, is degraded by type IV collagenase (CIVase) which usually exists in a latent form. The latent CIVase can be activated in vivo to an active form whose activity can be regulated by endogenous tissue inhibitor of metalloproteinase type II (TIMP2). As yet there is no specific biological, enzymatic or antibody based diagnostic kit commercially available with acceptable sensitivity for assaying CIVase or TIMP2. We have recently generated monoclonal antibodies (mAbs) against CIVase. These mAbs have been characterized by immunoprecipitation, Western blot, and immunocytochemical labeling of CIVase. We will use a similar approach to generate anti-TIMP2 mAbs and use these mAbs to develop quantitative enzyme-linked immunosorbent assay (ELISA), immunohistochemical and flow cytometry test for examining CIVase and TIMP2 level in the human body fluids and tissues. In phase II, we will use these mAbs to evaluate clinical correlations between CIVase and prognosis levels of patients with diseases involving the breakdown of basement membrane. We will also isolate cDNA coding for these anti- CIVase and anti-TIMP2 mAbs that show neutralization activity to generate single chain antigen-binding proteins or humanized chimeric antibodies. These molecules will be tested for potential therapeutic uses in wound healing, angiogenesis, treatment of rheumatoid arthritis and prevention of cancer metastasis.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
海外基金